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INTRODUCTION

Insulin receptor substrate 1 and 2 (IRS1 and IRS2) are adapter proteins that link signaling from ups tream a ctivators t o m ultiple dow nstream e ffectors. IRSs m odulate a nd coordinate multiple signaling cascades involved in normal growth, metabolism and survival suggesting that they m ay pl ay a role i n cancer. Indeed, IRSs are required for t he tr ansforming ability of many oncogenes and IRSs are elevated and hyperactive in many human tumors and high IRS1 levels are associated with poor prognosis in breast cancer. Adapter proteins have been shown to play an important r ole in e pidermal g rowth f actor r eceptor ( ErbB2/Her2/Neu) a mplified b reast can cer. However, there is little known about the IRS interaction with ErbB2 in cancer development and progression. Therefore, I hypothesized that ErbBs bind and phosphorylate IRSs, and that levels of IRSs will modulate ErbB-induced tumorigenesis.
During the first year of my progress report I addressed this hypothesis by examining the role of IRS2 in ErbB2-mediated tumorigenesis in transgenic mice. I crossed MMTV-ErbB2 and MMTV-IRS-2 m ice, ho wever I f ound t hat el evated IRS2 had n o effect upon E rbB2 i nduced tumorigenesis. I a lso e xamined a put ative i nteraction be tween E rbB2 a nd IRS1 a nd/or IRS2, however, I was unable to conclusively show this association in either mammary epithelial cells, or b reast can cer cells (detailed in m y first a nnual r eport). I t herefore officially ch anged m y statement of work to expand upon the role of IRSs in IGF-IR signaling in breast cancer.
IGF-IR i s a m ajor r egulator of growth, s urvival, a nd m igration a nd i nvasion. O nce the ligands IGF-I or IG F-II bind t o IGF-IR, i t act ivates a cas cade o f d ownstream s ignaling ev ents, the best characterized are the ERK1/2 and phosphatidylinositol-3'-kinase (PI3K) pathways (1).
IGF-IR is oncogenic, transforming NIH3T3 or mouse embryonic fibroblast (MEF) cells (2) . W e s howed t hat ov erexpression of a c onstitutively active IGF-IR in th e mo use ma mmary gland r esulted in r apid mammary tumorigenesis (3) , and t his w as t hen supported b y a s imilar observation us ing i nducible ove rexpression of w ild-type I GF-IR (4) . W e subsequently s howed that constitutive IGF-IR can transform immortalized mammary epithelial cells (MCF10A), and that growth of IGF-IR transformed mammary epithelial cells was blocked in vitro and in vivo by a new IGF-IR tyrosine kinase inhibitor (BMS-536924) (5) . This same inhibitor was found to be active a gainst m any b reast can cer cel l l ines, an d w as f ound t o r estore ap ical/basal p olarity to MCF7 breast cancer cells grown in matrigel (6) .
In b reast can cer s pecimens, IGF-IR i s de tected a t ve ry hi gh f requency a nd i s overexpressed compared to normal b reast and high s erum IGF-I levels p redict increased breast cancer risk (1). Numerous agents targeting IGF-IR have recently entered clinical trials, and early results ar e v ery encouraging (7) . T wo di fferent c lasses of a nti-IGF-IR in hibitors a re in development: m onoclonal a ntibodies w hich are hi ghly specific f or IGF-IR an d cau se downregulation of the receptor, and tyrosine kinase inhibitors which often cross-react and block insulin receptor (InsR) as well as IGF-IR action (7) .
The s ignificance o f t his r esearch p roject i s t he r ealization t hat I RSs a re n ot s imply mitogenic a nd m etabolic s ignaling elements, but t hat t hey ha ve num erous ot her f unctions t hat strongly i mplicate t hem i n c ancer de velopment a nd pr ogression. I be lieve t hat t his research project will i ncrease our unde rstanding of IRSs i n m odulating its u pstream r eceptors in can cer development and progression, and may provide evidence and strategies for inhibiting IRSs as a therapeutic strategy in breast cancer.
BODY 1) Research and Training Accomplishments
The B reast C enter at B aylor C ollege o f M edicine ( BCM) pr ovided a uni que t raining environment for m y graduate s tudies with m ultiple oppor tunities f or m e t o g row a s a young research scientist. In the past three years, I have taken full advantage of these opportunities and will outline my primary accomplishments here: For the work presented in this poster I received the San Antonio Breast Cancer Symposium Basic Science Scholarship (December 2009) -presented data in a talk at the Breast Disease Seminar (February, 2010) -submitted a f irst a uthor r esearch a rticle e ntitled " High IGF-IR a ctivity in tr iple-negative breast cancer correlates with sensitivity to anti-IGF-IR therapy" to Clinical Cancer Research. Manuscript had favorable reviews and was resubmitted with minor corrections. High IG F-IR act ivity i n tr iple-negative b reast can cer c ell l ines an d tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. In revision Clin Cancer Res 2010 -Defended my thesis in June 2010 and was awarded the PhD.
2) Research Project
During t he f irst year of t he pr oject, I m ainly focused on t he r ole of IRS2 i n E rbB2mediated tumorigenesis in transgenic mice. I found that: -Overexpression of IRS2 di d not a lter br anching m orphogenesis i n a dult E rbB2 overexpressing mice. -Overexpression of IRS2 ha d no a ffect upon E rbB2-induced ma mmary t umorigenesis, w ith median time to tumor formation of 30.5 weeks, respectively. -We obs erved similar rates o f lu ng m etastasis in MMTV-ErbB2 mice co mpared t o ErbB2/IRS2 bigenic mice. -Immunoprecipitation f ailed t o s how a n i nteraction be tween E rbB2 a nd IRSs i n bot h mammary epithelial cells and breast cancer cells (this was based upon a preliminary literature suggesting there would be an interaction). -Overexpression of ErbB2 didn't affect the activation status of IRSs.
The results of the first year showed that we could not clearly decipher the role of insulin receptor substrates (IRSs) in ErbB2 induced tumorigenesis in vivo. We submitted a revised statement of work for year 2 and 3 to expand our research project to other receptors such as IGF-IR for which IRSs serve as the main adapter proteins for downstream signaling. The new approved aims were: Determine the biological effect of IRS1 and IRS2 downregulation in the above model by examination of proliferation, apoptosis, and polarity in three-dimensional culture.
(Months 14-20).
Aim 2. Examine the importance of IRS levels on response of breast cancer cells and mammary epithelial cells to IGF-IR signaling (Months 12-24) i)
Correlate During my thesis, the majority of my work and success (and subsequent publication) came from Specific Aim 3. In Specific Aim 2 I participated in a large proteomic effort which is just being written up b y another student i n D r Lee's l aboratory (with m e as co -author). S pecific Aim 1 turned out to be technically challenging and is being continued in Dr. Lee's laboratory since my departure. I will now describe the results from each of the aims. We is olated ma mmary epithelial tu mor c ell l ines f rom MMTV-ErbB2 transgenic t umors a nd immunoblotted t hese t o s how t hat t hey e xpressed E rbB2 and IRS2. They also expressed IRS1 (data not shown). We had previously used used Dharmacon siRNA pools to knockdown human IRS1 and IRS2 in MCF-10A c ells w ith g ood success. U nfortunately t he knoc kdown of m ouse IRS-1 a nd I RS-2 using species specific siRNA was insufficient to reduce IRS levels for further study.
Specific
ii) Perform t ransient or s table knoc kdown of IRS1 or IRS2 l evels us ing s hort-term si/shRNA in MMTV-ErbB2 m ammary c ancer c ells and ex amine ef fects o n aci ni morphogenesis in three-dimensional culture and growth in soft agar (Months 12-16). Not performed due to the lack of knockdown in 1.i iii) Determine the biological effect of IRS1 and IRS2 downregulation in the above model by examination of proliferation, apoptosis, and polarity in three-dimensional culture.
(Months [14] [15] [16] [17] [18] [19] [20] . Not performed due to the lack of knockdown in 1.i Despite the lack of s uccess i n t his A im, t he L ee l aboratory c ontinues t o s tudy t he rol e of I RSs i n ErbB function, and is now using shRNA to knockdown IRSs for future studies.
Specific Aim 2. Examine the importance of IRS levels on response of breast cancer cells and mammary epithelial cells to IGF-IR signaling
 Correlate levels of IRSs with response to IGF-I and insulin in a large panel of breast cancer cell lines
To accomplish this aim we have collaborated with Dr Gordon Mills at UT MD Anderson Cancer C enter u sing the hi gh-throughput reverse p hase p rotein ar rays (RPPA) assay (8, 9 ) . In this assay, up to 1000 protein lysates are printed with five serial dilutions in duplicate on a glass slide (max 12,000 spots) and then each slide probed with an antibody. More than 150 antibodies are validated f or R PPA. We f irst s tarted w ith a n in itial d ose-finding pi lot s tudy for I GF-I a nd insulin. MCF7 cells were stimulated for 15mins with increasing doses of IGF-I and insulin, lysed and i nterrogated w ith ove r 100 a ntibodies b y R PPA (including I GF-IR, p -IGF-IR, a nd IRSs). The experiment was successful and we noted interesting differences in these signaling pathways.
Subsequently, t o correlate l evels of IRSs w ith r esponse t o I GF-I and i nsulin i n a l arge panel o f c ell lin es, w e repeated t he ex periment i n 23 b reast can cer c ell lin es, s tarved them overnight in SFM, and then incubated with 10nM IGF-I or 10nM insulin over a time course (0, 5min, 10min, 30min, 6hr, 24hr, 48hr). This was done in triplicate for a total of 621 lysates which were printed for RPPA analysis (over 150,000 data points). Bioinformatic analysis of this data is underway, how ever w e have m any i nteresting f indings. W e f irst pr oduced he atmaps of t he changes in protein expression or phosphorylation and noted three different types of response 1) MCF-7 like, 2) HER2-like, and 3) minimal to no r esponse (data now shown). We collaborated with a systems biologists (Prahlad Ram,UT MD Anderson Cancer Center) to develop algorithms which could model the response in the cell lines. Figure 2 shows response for 5 protein markers in MCF-7 stimulated with IGF-I. T he black dots are the raw data from t he RPPA and the red line is the computer modeled simulation of the data using ordinary differential equations (ODE) with mass particle swarm optimization. Dr Prahlad Ram's group then used the computer simulation to predict what would happen to each component in the IGF-IR signaling network (including IRS-1) when each component is inhibited. E xcitingly, this analysis showed that blockage of many pathways led to upregulation of IR S-1 phos phorylation a nd a ctivity, and t hat IRS-1 i s a m ajor c omponent t hat ne eds t o b e silenced in breast cancer cells. This is shown in Figure 3 , where inhibition of proteins on the Xaxis results in changes in proteins listed on the Y-axis. Note that in the two cell lines shown, loss of IR S-1 ha s a m ajor i mpact upon a ll s ignaling m olecules i n t he I GF pa thway, i ndicating t hat IRS1 is a critical signaling node in this pathway. 
 Determine the effect of loss of IRS-1 and IRS-2 on IGF-IR disrupted mammary acini formation (CD8-IGF-IR-MCF10A cells)
This was not performed due to the expansion and development of Aim 3.
 Test the effect of IRS knockdown on IGF-IR-mediated epithelial to mesenchymal transition and transformation
Specific Aim 3. Identify biomarkers for response to IGF-IR and subsequent sensitivity to an IGF-IR small tyrosine kinase inhibitor
Use transcriptomic profiling of a large panel of breast cancer cell lines to identify markers of sensitivity and resistance to an IGF-IR tyrosine kinase inhibitor
The lack of biological effect of IRS2 on ErbB2 induced tumorigenesis in the transgenic mice led us to expand our r esearch project to the IG F-IR r eceptor f or w hich IRSs s erve as t he m ain adapter pr oteins f or do wnstream s ignaling. Experimental s tudies in vitro and in vitro have provided substantial evidence for a role of IGF-IR in human breast cancer. Overexpression of a constitutively act ive IGF-IR or i nducible ove rexpression of w ild-type I GF-IR i n t he m ouse mammary gland r esults in r apid mammary tumorigenesis (3, 4) . C onsistent w ith th is, overexpression of IGF-IR transforms immortalized mammary epithelial cells (MCF10A) (5, 10, 11) . Clinical studies support the importance of IGFs in breast cancer. In breast cancer specimens, IGF-IR i s detected at v ery high frequency and i s overexpressed compared t o normal breast. In addition, high serum IGF-I levels predict increased breast cancer risk (7) .
To identify markers for response to IGF-IR therapy and subsequent sensitivity to an IGF-IR s mall t yrosine ki nase i nhibitor w e us ed a bi ased a nd a n unbi ased a pproach. In t he b iased approach we used an 'IGF-I gene signature' pattern of genes up-or down-regulated by IGF-I that we previously reported (12) . The IG F-I gene signature was derived from MCF7 cells that were starved over night and then stimulated with IGF-I for 3 hour s and 24 ho urs. RNA was isolated and microarray analysis was performed. Only genes modulated by IGF-I at both time points were included i n t he IG F-I gene s ignature. In a ddition, we at tempted t o r educe t he i mportance o f proliferative genes b y 1 ) r emoving genes an notated as b eing as sociated w ith p roliferation i n Gene O ntology ( GO), a nd 2) r emoving genes t hat w ere found t o be i nduced i n f ibroblasts stimulated to proliferate by serum (12) . In our previous report we found that this IGF signature was present in human breast cancers, specifically the subtypes luminal B and TNBC (12) . Triplenegative b reast c ancers ( TNBC) ar e ch aracterized b y l ow t o ab sent ex pression o f E R, progesterone receptor ( PR) a nd H ER-2 (13, 14) and a ccount f or up t o 20-25% of a ll br east cancers. TNBC currently has no t argeted therapies, and often responds poorly to chemotherapy (15) . T NBC p referentially affects younger w omen an d A frican-American w omen, a nd i s associated with high histological grade and aggressive clinical behavior (16) .
We first set out to ex amine the effect of IGF-IR inhibitors on the IGF-I gene signature. We reasoned that regulation of genes by IGF-I (which made up t he IGF gene signature) should be r eversed b y anti-IGF-IR i nhibitors. C onsistent w ith t his, w hen w e examined t he l evels of genes we pr eviously f ound t o be i nduced or r epressed b y IGF-I i n ne uroblastoma x enografts treated w ith an an ti-IGF-IR (h10H5, G enentech) a ntibody (17) , w e f ound t hat t here w as a striking r eversion i n t heir l evels ( Fig. 4A ). Thus, ge nes i nduced b y IGF-I i n M CF7 cel ls w ere repressed b y h10H 5 t reatment of t he ne uroblastoma x enograft, a nd genes r epressed b y IGF-I were now i nduced. T his r esult w as hi ghly significant ( Fig 4D, S pearman's r ank s um p~0). Highly s imilar r esults w ere o btained w ith a n IGF-IR t yrosine ki nase i nhibitor ( A-928605, Abbott) (18) that w as a dministered in vitro to N IH3T3 f ibroblasts t ransfected w ith t he IGF-IR ( Fig. 4B ). F inally, w e g enerated g ene expression data from co lon cancer x enografts (G EO) grown in vitro and t hen t reated w ith a n a nti-IGF t yrosine ki nase i nhibitor B MS-754807 (12.5mg/kg/day) f or va rious t ime-points of 1, 6 and 24 hour s a nd 15 da ys. T reatment of t hese GEO x enografts resulted i n gene e xpression va lues t hat were a gain r eversed compared t o t he IGF-signature ( Fig. 4C ). N ote t hat t here was no change i n t he IGF s ignature a fter 1 hour , but after 6 hours of exposure to the drug a strong reversion of the IGF signature was seen, which is entirely consistent w ith th e pharmacodynamics a nd pha rmacokinetics of B MS-754807. This data gives us confidence that our signature can measure IGF activity, and furthermore, suggests that the IGF signature might be a predictor of cells that have an active IGF pathway and thus may response to an IGF-IR inhibitor. Thus, the IGF-gene signature itself might be a marker of sensitivity and resistance to IGF-IR therapy. For A-C, relative gene expression is represented using a yellow-blue color scale; patterns for genes that are upregulated (yellow) in the IGF gene signature are separate from the patterns for genes that are downregulated (blue). D. Statistical enrichment of the MCF7 IGF-I signature gene sets within each of the indicated IGF-I inhibitor treatment ex pression pr ofile d atasets. All ge nes r epresented i n t he IGF-I i nhibitor dat aset were f irst ranked by expression in inhibitor/control (using two-sided t-test), then the overall positions of the MCF7 gene sets within the ranked lists was assessed by Spearman's rank sum (positive rank sum, associated with i nhibitor gr oup; ne gative r ank s um, as sociated w ith c ontrol gr oup). I n a ll t hree dat asets, t reatment with IGF-IR inhibitors reversed expression of the IGF regulated genes.
To f urther i dentify m arkers of s ensitivity a nd resistance t o an IGF-IR tyrosine ki nase inhibitor w e us ed an unbi ased t ranscriptomic a pproach by performing comparative g ene expression analysis between sensitive and resistant breast cancer cell lines to BMS-754807 (19) 3) . Compared to all cell lines, the TNBC group was enriched for cell lines with low IC 50 (p<0.01, Spearman's rank sum, two-sided). We then performed comparative gene expression analysis between the ten most sensitive cell lines with an IC 50 below 4µM and the 9 most resistant cell lines with an IC 50 above 14µM BMS-754807 using gene ex pression data published b y Neve et al (20) . This analysis identified 136 probe sets corresponding to 114 genes (p < 0.001 and FDR < 5 %) that were differentially expressed b etween s ensitive an d r esistant cel l l ines. T he t op 10 di fferentially e xpressed genes were validated by qRT-PCR in a panel of seven sensitive and six resistant breast cancer cell lines (Fig. 6 ). We identified that most of these 114 genes were actually markers of the basal or luminal subtype w ith s ensitive c ell l ines e xpressing ba sal m arkers s uch as C AV1 a nd C AV2 w hereas resistant cell lines expressed luminal markers such as ErbB3 and SPDEF. 
Test whether response of cells to the IGF-IR inhibitor is correlated with markers identified in Aim 3.1
In the previous aim 3.1 we identified markers of response to an IGF-IR tyrosine kinase inhibitor. Based on aim 3.1 we proposed that the IGF signature might be a predictor of cells that have an active IGF pathway and thus may response to an IGF-IR inhibitor. To test whether the presence of the IGF signature correlate with the response of cells to an IGF-IR inhibitor, we first examined the us efulness of t he IGF gene s ignature i n pr edicting pa tients w ho m ay respond t o anti-IGF-IR t herapy. T herefore, we s tudied c ell lines g rown i n c ulture, where on e c an rapidly assess r esponse and an alyzed the IG F-I gene s ignature i n a publ icly available d ataset o f g ene expression profiles from a large panel of breast cancer cell lines (20) . Figure 7A shows a panel of breast cancer cell l ines ar ranged ac cording t o t heir i ntrinsic s ubtype ( as d efined u sing t he Hoadley d ataset (21) ). T he IGF s ignature i s p resent i n t he m ajority o f b asal-like ( and T NBC) breast cancer cell lines. We assigned each cell line a t-score based upon the similarity of its gene expression profile to the IGF signature and the positive t-score in the majority of TNBC cell lines highlights the presence of the signature in this subtype (Fig. 7B ). This data is entirely consistent with our previous report of the IGF signature in TNBC (12) suggesting that the IGF-IR pathway is highly active in the triple-negative/basal-like subtype of breast cancer. 20)) were f irst n ormalized t o t he m edian b efore computing t he t -score. F or eac h gene t ranscription pr ofile d ataset, we as signed i ntrinsic m olecular subtypes to the cell lines, essentially as previously described (22) , using the human tumor dataset from Hoadley et al. (21) to define the subtype-specific expression patterns.
To test whether the IGF signature is a marker of sensitivity and resistance to an IGF-IR tyrosine kinase inhibitor BMS-754807 we plotted the t-score for the IGF gene signature for each cell line against the IC 50 (as determined in aim 3.1). There was a significant inverse correlation (r=-0.41, p= 0.014), w ith a hi gher t -score (indicating an act ive IGF p athway) b eing as sociated with a g reater r esponse ( lower IC 50 ) t o BM S-754807 ( Fig. 8) . These data confirms that the response of cells to BMS-754807 correlates with the IGF-gene signature. In addition, this analysis highlights that BMS-754807 is specifically active in TNBC. In t he unbi ased a pproach of a im 3.1 w e i dentified 114 g enes t hat w ere di fferentially expressed between sensitive and resistant cell lines. We found that most of these 114 genes are markers of the basal or luminal subtype with sensitive cell lines expressing basal markers such as CAV1 an d C AV2 w hereas r esistant c ell l ines ex pressed l uminal m arkers s uch as E rbB3 an d SPDEF. To pr oof t hat t hese m arkers c orrelate t o t he r esponse of c ells t o t he IGF-IR i nhibitor BMS-754807 w e n ext an alyzed t he 1 14 genes in a p anel o f 5 1 b reast c ancer cell l ine p rofiles with known and unknown IC 50 to BMS-754807 (20) . Hierarchical clustering separated the cells lines into two major bins: ER-negative cell lines that were s ensitive and ER-positive cell lines that were mostly resistant ( Fig. 9 ). To validate this clustering data, we determined the sensitivity to BMS-754807 of breast cancer c ell l ines w ith a n unknow n IC 50 by M TS-assay. A mong th e cell lin es te sted th e T NBC cell lines SUM149PT and MCF10A showed the greatest response to BMS-754807 whereas cell lines that are ER negative but overexpress Her2 (SUM225 and SUM190PT) are less sensitive to BMS-754807 ( Fig. 8 and Table 1 ). Luminal breast cancer cell lines such as ZR75B, MDA-MB-175VII a nd M DA-MB-316 s howed t he l east r esponse t o B MS-754807. In summary, these experiments showed that 114 genes are markers that correlate with response of cells to the IGF-IR inhibitor BMS-754807. In addition, we could confirm that BMS-754807 is especially active in TNBC cell lines. 
Examine if an IGF-IR inhibitor is effective in breast cancer xenografts identified as having an active IGF-IR pathway
Preclinical can cer r esearch h as r elied h eavily u pon cel l l ines g rown i n cu lture an d t hen xenografted fo r growth i n m ice. H owever, r ecent w ork ha s s hown t hat h uman c ancers pl aced directly into the mouse (tumorgrafts) maybe a more appropriate model that is better at predicting response to drugs in humans (23) . We have recently developed several new tumorgraft models of human T NBC. W e screened s even TNBC t umorgrafts f or a ctivity o f t he IGF-IR b y bot h immunohistochemistry ( IHC) and i mmunoblotting ( IB). Figure 11A s hows t hree r epresentative tumorgrafts e xpressed va rious l evels of IGF-IR an d h ad d ivergent l evels o f act ive phosphorylated pY-IGF-IR. We generated gene expression data from all of the tumorgrafts and calculated an IGF signature t-score for each tumorgraft. Analysis of these profiles showed that tumorgraft MC1 (24) had the highest level of IGF-IR and pY-IGF-IR, and in addition had a high IGF s ignature t -score. P rotein l ysates f rom th e s ame tu morgrafts a s in F ig 11A c onfirmed t hat MC1 ha d t he hi ghest a ctivation of IGF-IR ( Fig. 11B) . A ctivation of downstream s ignaling molecules v aried am ong the t umorgraft m odels. M C1 ha d hi gh l evels of IRS1 a nd a ctivated AKT whereas the tumorgraft 2665A showed activation of MAPK. Figure 11 . TNBC human tumorgrafts express high levels of IGF-IR A. Three different TNBC human tumorgraft lines (2147, 2665A, MC1) were harvested and processed in paraffin. Immunohistochemistry was performed for anti-pY-IGF-IR (Phospho-IGF-IR) and total IGF-IR. Microarray analysis was performed on t hese t umorgrafts. B ased on t he g ene ex pression d ata a n I GF s ignature t-score w as ca lculated f or each tumorgraft as indicated underneath the representative picture. B. The same three tumorgraft lines were lysed and analyzed by immunoblot and probed using IGF-IR specific antibodies as well as total/phospho-specific antibodies for IRS1, AKT, ERK1/2. ß-actin was used as a loading control. Tumorgraft lines that were not relevant to this study were cropped out between 2665A and MC1.
Our s tudies in A im 3.1 a nd 3.2 identified T NBC cel l l ines as h aving an act ive IGF pathway. As we previously showed that BMS-754807 is most active in TNBC cell lines in vitro (Aim 3.1 and 3.2), we directly examined the effectiveness of the IGF-IR inhibitor BMS-754807 in the MC1 tumorgraft model of TNBC breast cancer alone as a single agent or in the presence of chemotherapy (docetaxel). We chose the tumorgraft MC1 for this preclinical study as it showed the highest levels of active and total IGF-IR and also a hi gh IGF t -score ( Figure 11 ). A r ecent study examining timing of anti-IGF-IR therapy and chemotherapy in cells in culture showed that most efficacious combination was chemotherapy followed by anti-IGF-IR therapy (25) . We thus administered d ocetaxel f ollowed b y B MS-754807 t he ne xt da y. S ingle a gent BMS-754807 achieved a statistically significant (p<0.001) reduction in tumor growth when compared with the control gr oup ( Fig. 12A ). D ocetaxel s tabilized M C1 t umor g rowth. S trikingly, combined treatment w ith BMS-754807 a nd do cetaxel s howed s uperior t umor growth i nhibition t o e ither single agent alone (p<0.001), and four out of six mice receiving the combined agents had tumors regress until no tumor was palpable. pY-IGF-IR
IGF-IR
To confirm the ability of BMS-754807 to inhibit IGF-IR activity in triple negative breast cancer, tyrosine phosphorylation and total level of IGF-IR was examined in the various treatment groups. B oth p -IGF-IR a nd IGF-IR s howed membrane s taining w ith a s mall amount o f cytoplasmic s taining ( Fig. 10B ). T here w as no c hange i n t he l evels of pY -IGF-IR b etween tumors treated w ith d ocetaxel o r v ehicle (Fig. 12B ). I n c ontrast, B MS-754807 c ompletely blocked I GF-IR phos phorylation. T here was no c hange i n l evels of t otal IGF-IR be tween t he different treatment groups.
We ne xt a nalyzed t he h istology of t he t umors among t he different t reatment gr oups. Several reports have shown that chemotherapy agents such as docetaxel affect the stability of the microtubules a nd i n doi ng s o i nduce m itotic c atastrophe (26, 27 ) . M itotic c atastrophe r esults from aberrant mitosis, or missegregation of chromosomes followed by cell division which results in th e f ormation o f mu ltinucleated giant c ells le ading to cell death. C ell death th rough mito tic catastrophe may occur through apoptosis as well as necrosis (27) . MC1 tumorgrafts treated with Docetaxel showed relatively few multinucleated giant cells (Fig. 11A) . However, the addition of BMS-754807 dramatically increased docetaxel-induced mitotic catastrophe (Fig. 13A ). Analysis of H&E staining showed that normal breast cancer cells were still present in Docetaxel treated tumors whereas only multinucleated cells were present in the combination treated tumors.
Since mu ltinucleated c ells ma y b e te mporarily v iable a nd mito tic c atastrophe ma y b e a process l eading t o d eath (27) , w e a nalyzed t reated t umors f or r eplication, pr oliferation, a nd apoptosis. A ll t reatment gr oups s howed a r eduction i n r eplication as i ndicated b y less B rdU incorporation i nto D NA c ompared t o unt reated t umor c ells ( Fig. 13B) . BMS-754807 a lone reduced replication b y 3 6% ( 22% B rdU pos itive c ells i n ve hicle t umors ve rsus 16% i n t reated tumors) but this was not significant (adjusted p-value=0.13). Chemotherapy significantly reduced replication by 55% (adjusted p-value=0.015) and the combination by 59% compared to vehicle (adjusted p -value= 0.0018). W e n ext an alyzed p roliferation as as sessed by Ki67 p ositive c ells ( Fig. 13 C a nd E ) . W hereas bot h s ingle a gents a lone w ere able to s ignificantly reduce proliferation by 30-32% (adjusted p-values < 0.0001), combination treatment resulted in only a 17% r eduction i n pr oliferation ( adjusted p -value < 0.005, c ompared to ve hicle). W e t hen investigated w hether s ingle a gents a lone or t he c ombination of B MS-754807 a nd D ocetaxel induces cell death. BMS-754807 caused a 4-fold elevation in apoptosis as measured by cleaved caspase 3 ( CC3) f rom 3% a poptotic c ells i n v ehicle t reated t umors t o 11% i n B MS-754807 treated tumors ( Fig. 13D and E), however this elevation was not significant (adjusted p-value = 0.36). Chemotherapy resulted in a 6.7-fold induction of apoptosis compared to vehicle (adjusted p-value=0.1) which again wasn't significant, whereas the combination caused a striking 12-fold induction of apoptosis ( Fig. 13D and E) which was highly significant (adjusted p-value=0.005). In addition, combination therapy resulted in massive cell destruction through necrosis as shown in Figure 13A .  Applied for and received a position at Grunenthal Group, a large pharmaceutical companty
CONCLUSION
In Aim 1 I focused on t he role of IRS2 i n ErbB2-mediated t umorigenesis i n t ransgenic mice. This study was based upon an exciting proteomic study which suggested that there might be an interaction. However, we found that overexpression of IRS2 didn't affect ErbB2-induced tumorigenesis and metastasis. Therefore, I expanded the research project to other receptors such as IGF-IR for which IRSs serve as the main adapter proteins for downstream signaling. In Aim 2 I examined IGF s ignaling i n a p anel o f b reast c ancer cell l ines t o co rrelate l evels o f IRS w ith response t o IGF-I a nd i nsulin. We us ed r everse pha se pr oteomic arrays t o de velop pr oteomic profiles of both insulin and IGF-I action in 23 breast cancer cell lines. Computer simulations of this data identified IRS1 as a critical signaling node which needs to be inhibited in breast cancer cells. In Aim 3 I expanded the study outside of IRSs to identify biomarkers for response to IGF-IR a nd s ubsequent s ensitivity t o a n IGF-IR s mall t yrosine k inase in hibitor. Originally, the laboratory pr eviously developed t he IGF s ignature t o l earn m ore a bout t ranscriptional e vents downstream o f IGF-IR, and t o e xamine t he r ole of IGF-IR r egulated g enes in breast can cer. However, the obvious question as to the potential role of the IGF signature in predicting response to anti-IGF-IR therapy arose. We showed here that the IGF signature can measure IGF activity in tumors and that the IGF signature weakly correlated (r=0.41) with response of cells to an IGF-IR inhibitor. The strength of the signature may come when used in combination with IGF-IR protein levels and activity as potential marker for response to IGF-IR therapy. Therefore, IGF-IR alone, or t he IGF s ignature a lone m aybe i nsufficient to i ndicate a n a ctive IGF pa thway, but t he combination m ay yield better pr ediction. T o t his e nd, w e us ed t his s trategy t o s elect a T NBC tumorgraft for study and found dramatic effects of an IGF-IR inhibitor. Further comprehensive studies a re r equired t o de finitively prove w hether t he c ombination of IGF-IR l evels and downstream gene t ranscripts i s a us eful m ethod for i dentify p atients who may r espond t o anti-IGF-IR therapy.
I have been extremely f ortunate t o obt ain pr e-doctoral t raining i n a n out standing environment at Baylor College of Medicine. I hope that my studies will continue the movement to ta rgeting IGF-IR i n b reast can cer, and I fully ex pect t hat IRSs w ill c ontinue t o de velop a s critical biomarkers for response to IGF-IR inhibitors.
